Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Avidity Biosciences Announces U.S. Managed Access Program for Investigational Therapy del-zota in DMD44
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE Phase 1/2 Trial in People Living with DMD44
Metalsource Mining Intersects 48.04 g/t AuEq over 12.62m, Including 210.72 g/t AuEq over 2.74m, Extends Mineralization down Dip 195m, Continues to Expand Gold, Silver and Base Metal Mineralization
EnerCom Opens Registration for the 31st Annual Energy Investment Conference August 17-19, 2026 in Denver, Colorado
QIMC Details Multiple Shallow Hydrogen-Bearing Zones in Drill Hole 26-02 and Advances Integrated Interpretation of Holes 1 and 2; Drill Hole 2 to be Extended to 700 Metres; Drill Mobilized for Hole 3
